Drugs / Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03178552 | Sep 2017 → Jun 2027 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | Mixed |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03178552 ↗ |